You are here

  • Home
  • Archive
  • Volume 15, Issue 1
  • Immunotherapy in stage IV non-small cell lung cancer in a patient with Grave’s disease: safety and biomarkers of response

Article Text

Article menu
Download PDFPDF
Case report
Immunotherapy in stage IV non-small cell lung cancer in a patient with Grave’s disease: safety and biomarkers of response
  1. Marta Vilaça1,
  2. Catarina Silva2,
  3. Fernanda Estevinho1 and
  4. Helena Magalhães1
  1. 1Oncology Department, Pedro Hispano Hospital, Matosinhos, Portugal
  2. 2Imagiology Department, Pedro Hispano Hospital, Matosinhos, Porto, Portugal
  1. Correspondence to Dr Marta Vilaça; martamvilaca{at}gmail.com

Abstract

Patients with cancer and pre-existing autoimmune diseases have been excluded from immunotherapy clinical trials. So, studying these patients who received immunotherapy is critical to increasing evidence of the treatment’s safety and efficacy in this population. Furthermore, a complete and durable response to immunotherapy in metastatic non-small cell lung cancer (NSCLC) is rare. Therefore, it is imperative to study patients with a complete response in order to identify potential predictors of response to immunotherapy. In this case report, we highlight a 62-year-old man with a smoking history and Graves’ disease who achieved a complete response with immunotherapy for metastatic NSCLC, with a long-lasting response and no immune-related adverse events. Male gender, high programmed death-ligand 1 expression, current smokers, epidermal growth factor receptor and anaplastic lymphoma kinase wild types could be biomarkers of response to immune checkpoint inhibitors presented at baseline. Caution should be exercised when interpreting this finding because it represents our patient.

  • immunological products and vaccines
  • thyroid disease
  • lung cancer (oncology)
  • safety
  • therapeutic indications

https://doi.org/10.1136/bcr-2021-245632

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors were involved in the case management and treatment decision. MV was wright the case and made the literature review. CS selects the CT scan images and reviews the final script. FE reviewed the final script and approved it. HM supervised MV in the literature review, reviewed the preliminary and final version of the script. All authors read the final version and give their approval.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.